Richard Smalling, MD
Cardiovascular Disease · Houston, TXNPI 1093733321
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (38.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 62.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $23,141 and has fallen 96.2% since, to $874 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $217.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$28K
- Edwards Lifesciences$8K
- Medtronic$6K
- Boston Scientific$931
- W. L. Gore & Associates, Inc.$578
- Bard Peripheral Vascular, Inc.$429
- plus $717 from 6 others
Across 219 payments — averaging $3941.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$428K
- Edwards Lifesciences$415K
- Canon Medical Systems Corporation$20K
What the payments were for
- Consulting fees$17,14939%
- Speaking & faculty fees$11,56926%
- Travel & lodging$5,40012%
- Food & beverage$9,83822%
- Other$2821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 80 | $27,556 |
| Edwards Lifesciences | 27 | $7,961 |
| Medtronic(2 entities) | 50 | $6,064 |
| Boston Scientific | 13 | $931 |
| W. L. Gore & Associates, Inc. | 10 | $578 |
| Bard Peripheral Vascular, Inc. | 12 | $429 |
| Canon Medical Systems USA, Inc. | 5 | $367 |
| Teleflex LLC | 2 | $151 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $99 |
| Arrow International, Inc. | 1 | $40 |
| Cardiva Medical, Inc. | 1 | $37 |
| AstraZeneca | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$19,680
- Edwards SAPIEN 3 Transcatheter Heart Valve$5,874
- AMPLATZER TALISMAN$2,925
- AMPLATZER$1,587
- CoreValve Evolut$774
- Mitra Clip system$507
- SAPIEN 3 Ultra RESILIA$367
- NAVITOR$294
- PORTICO$282
- MitraClip$254
- APOLLOTM$183
- COMET$175
- Allure CRT Pacemaker$174
- AVVIGO Guidance System$166
- Product in Development$146
- iLab Ultrasound Imaging System$145
- Resolute$133
- VASCBAND$127
- AMPLATZER AMULET$127
- Endurant$125
How this compares
$44,237 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $132,922 |
| Repatha SureclickEvolocumab | 55 | $49,807 |
| JardianceEmpagliflozin | 36 | $47,490 |
| BrilintaTicagrelor | 41 | $43,596 |
| XareltoRivaroxaban | 18 | $16,871 |
| FarxigaDapagliflozin Propanediol | 15 | $14,920 |
| EntrestoSacubitril/Valsartan | 12 | $10,157 |
| Metoprolol Succinate | 300 | $6,760 |
| Repatha SyringeEvolocumab | 12 | $6,295 |
| Ezetimibe | 120 | $3,794 |
| Torsemide | 153 | $3,367 |
| Nifedipine ErNifedipine | 120 | $3,303 |
| Amiodarone Hcl | 46 | $2,989 |
| Lisinopril | 224 | $2,581 |
| Ranolazine ErRanolazine | 12 | $2,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $22 | $58,51656 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Biykem BozkurtHouston$606K
- Reynolds DelgadoHouston$471K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.